Private Placement Strengthens Funding Position
Agenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of its clinical pipeline.
The financing also includes purchase warrants that could generate an additional $255 million if fully exercised, bringing the total potential value of the transaction to $340 million.
Leading Healthcare Investors Back the Deal
The private placement was led by Commodore Capital, with participation from several existing and new institutional investors, including RA Capital Management, TCGX, Invus and Ligand Pharmaceuticals.
According to the company, the proceeds will primarily be used to fund its Phase 3 ROBBIN clinical trial.
Assuming all warrants are exercised, Agenus expects the financing to provide sufficient cash to support operations through the end of 2031.
Company Refocuses Clinical Development Strategy
Alongside the financing announcement, Agenus said it plans to discontinue financial support for the BATTMAN Phase 3 study evaluating a treatment for late-line metastatic microsatellite stable (MSS) colorectal cancer.
The move reflects the company’s decision to prioritise resources toward programmes it believes offer stronger long-term development opportunities.
Capital Raise Supports Long-Term Pipeline
The new financing provides Agenus with additional flexibility as it advances its late-stage clinical portfolio while extending its projected cash runway.
Investors responded positively to the announcement, with the stock moving sharply higher in premarket trading following confirmation of the funding package.
Agenus stock price
